Morgan Stanley lowered the firm’s price target on Biohaven (BHVN) to $26 from $54 and keeps an Overweight rating on the shares. After the company received a Complete Response Letter from the FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback